{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:35:31Z","timestamp":1761896131208},"reference-count":12,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.beha.2015.10.002","type":"journal-article","created":{"date-parts":[[2015,10,25]],"date-time":"2015-10-25T07:40:59Z","timestamp":1445758859000},"page":"69-72","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Reasons for optimism in the therapy of acute leukemia"],"prefix":"10.1016","volume":"28","author":[{"given":"Jacob M.","family":"Rowe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2015.10.002_bib1","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1182\/blood-2015-01-561373","article-title":"Current challenges in clinical development of \u201ctargeted therapies\u201d: the case of acute myeloid leukemia","volume":"125","author":"Estey","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.10.002_bib2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/MOH.0000000000000018","article-title":"New strategies for relapsed acute myeloid leukemia: fertile ground for translational research","volume":"21","author":"Dinner","year":"2014","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.beha.2015.10.002_bib3","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.24072","article-title":"Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML","volume":"90","author":"DiNardo","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2015.10.002_bib4","article-title":"AG-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant metabolic enzyme, induces durable remissions in a phase 1 study in patients with IDH2 mutation positive advanced hematologic malignancies","volume":"124","author":"Stein","year":"2014","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.beha.2015.10.002_bib5","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2015.10.002_bib6","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2015.10.002_bib7","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1056\/NEJMe1412902","article-title":"Clone wars\u2013the emergence of neoplastic blood-cell clones with aging","volume":"371","author":"Abkowitz","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2015.10.002_bib8","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2015.10.002_bib9","article-title":"High dose daunorubicin improves survival in AML up to age 60, across all cytognetic risk groups including patients with unfavorable cytogenetic risk, and FLT3-ITD mutant AML: updated analyses from eastern cooperative oncology trial E1900","volume":"124","author":"Luskin","year":"2014","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.beha.2015.10.002_bib10","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1182\/blood-2012-07-441030","article-title":"Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL","volume":"120","author":"Topp","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.10.002_bib11","first-page":"S20","article-title":"MRD monitoring in ALL","volume":"94","author":"Bruggemann","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2015.10.002_bib12","article-title":"Efficacy and safety of inotuzumab ozogamicin (INO) vs standard of care (SOC) in salvage 1 or 2 patients with acute lymphoblasic leukemia (ALL): an ongoing global phase 3 study","author":"DeAngelo","year":"2015","journal-title":"EHA Learning Center"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692615000201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692615000201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T09:53:16Z","timestamp":1537264396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692615000201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":12,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S1521692615000201"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2015.10.002","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reasons for optimism in the therapy of acute leukemia","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2015.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}